Mar. 18 at 11:24 PM
$KZIA Acknowlege earlier correct information. News today replicates a similar disclosure 4 ago, which afforded the company authority to raise
$100M. Such funding has subsequently been raised, to progress pAX. More specifically this time when it is appropriate, these funds may be used in a registrational Phase 2/3 FDA trial, in metastatic cancers or Parkinson Disease. The company still has
$45M cash. No drug has more potential to leverage off the new approach being undertaken by the FDA, to get drugs to market faster. Celcuity was capped at one billion prior to the start of their Phase 3. But a registration study in a-syn Parkinsons may eclipse the billion-dollar float size. Paxalisib is a drug of outstanding potential - not reflected by its current share price. It is a totally unique drug, that works in the brain, such to repair PI3K pathway aberrations in human disease. The pathway regulates various human cellular functions, growth, survival, and metabolism.
